Lunit
| Market cap | ₩1.1T |
| PE ratio | – |
| Forward PE | – |
| PB ratio | 3.29 |
| EPS | −₩864 |
| Dividend (yield) | – |
| Analysts (1–5) | – |
| Price target | – |
| Volume | 5,813,828 |
| Trading value | ₩86.9B |
| Day’s range | ₩14,260 – ₩15,800 |
| 52-week range | ₩8,180 – ₩24,550 |
| Foreign ownership KR | 7.82% |
| Foreign net buy (Oct 26) KR | +187,190 sh |
| Book value / share | ₩4,454 |
| Founded | 2013 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 26 | ₩14,690 | +187,190 | +289,657 | −268,852 | 7.82% |
| Oct 23 | ₩11,300 | −30,639 | +68,151 | −37,482 | 7.36% |
| Oct 22 | ₩11,270 | +68,199 | −19,635 | −48,968 | 7.70% |
| Oct 21 | ₩11,510 | −305,220 | −89,128 | +395,127 | 6.92% |
| Oct 20 | ₩12,660 | −94,584 | +67,350 | +40,371 | 7.47% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩25.1B | ₩54.2B | ₩83.1B | – |
| Operating income | −₩42.2B | −₩67.9B | −₩83.1B | – |
| Net income | −₩36.8B | −₩82.7B | −₩47.4B | – |
| Operating margin | −168.33% | −125.41% | −99.97% | – |
| Return on equity | −24.21% | −41.57% | −31.57% | – |
| Debt-to-equity | 13.96% | 166.03% | 169.16% | – |
| EPS | −₩645 | −₩1,341 | −₩760 | – |
| Dividend per share | – | – | – | – |
Peers
| Seers 458870 | ₩26,300 | −5.57% |
| Infinitt Healthcare 071200 | ₩10,460 | −1.60% |
| Sky Labs 386380 | ₩11,010 | +3.09% |
| 3billion 394800 | ₩5,580 | −1.24% |
| GC MediAI 032620 | ₩2,870 | −1.37% |
| Solborn 035610 | ₩4,780 | +0.84% |
About
Lunit is a deep-learning medical AI company that provides reading support solutions for cancer screening images and solutions that predict response to immuno-oncology treatment. Its 2024 acquisition of Lunit International Ltd. laid the groundwork for an integrated platform covering the full breast cancer screening cycle, and it is expanding through partnerships and joint research with global companies. Founded in 2013, it listed on the KOSDAQ in 2022.
Lunit Inc. is listed on the KOSDAQ market of the Korea Exchange under the ticker 328130. Industry: Software & game publishing.
Lunit in our notes
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 27, 2026; investor flows as of Oct 26, 2026. Delayed data, not investment advice.